Appearing as a noteworthy breakthrough in the fight against obesity, the drug is capturing considerable interest . This treatment combines the action of two recognized GLP-1 binding agonists, semaglutide , and an additional glucose-dependent incretin component. Initial patient data have indicated significant fat loss in patients with a high BMI ,